Why We Invested in Linear Health Sciences — and Why Dr. Robert C. Robbins Just Joined Their Team
By Plains Ventures | March 25, 2026
At Plains Ventures, we invest in early-stage companies solving high-value problems. That mandate sounds simple, but in practice it means looking for a specific combination: a real problem that costs the healthcare system real money, a founder with the conviction to solve it, and a product that actually works.
Linear Health Sciences checks every one of those boxes.
Today, we’re proud to share that Dr. Robert C. Robbins, MD has joined Linear Health Sciences as Chief Medical Officer and Board Member — and we couldn’t be more excited about what this means for the company and the patients it serves.
The Problem Linear Is Solving
IV catheter dislodgement is one of those problems hiding in plain sight. It happens constantly — in ICUs, in surgical suites, in outpatient settings — and the consequences range from patient discomfort to serious complications. Collectively, it accounts for over $2 billion in preventable waste annually in U.S. healthcare systems alone.
Linear’s solution is the Orchid Safety Release Valve (SRV) — a tension-activated breakaway safety device engineered to reduce the risk of IV catheter dislodgement and protect both patients and clinicians. It’s elegantly simple, which is exactly what the best medical device innovations tend to be.
Why Dr. Robbins
When you’re building a medical device company, credibility with clinicians and health systems isn’t a nice-to-have — it’s the whole game. That’s what makes Dr. Robbins’ addition so significant.
His career spans three decades at the highest levels of medicine, research, and health system leadership:
Pioneering cardiac surgeon and board-certified by both the American Board of Surgery and the American Board of Thoracic Surgery
22nd President of the University of Arizona, where he significantly expanded research funding and institutional impact
President and CEO of Texas Medical Center — the world’s largest medical center — where he led the creation of the TMCx Innovation Institute, which has fostered more than 220 healthcare startups and facilitated over $5.8 billion in funding
Instrumental in launching more than 50 biotech, medical device, and life sciences companies
Currently serves as a Distinguished Visiting Fellow at the Hoover Institution at Stanford University and holds a tenured faculty position at the University of Arizona Department of Surgery
In his own words: “Loss of venous access is one of the most common — and underestimated — challenges in modern medical care. The Orchid is an elegant, practical solution to a universal problem. Its ability to protect IV access has the potential to significantly improve patient safety, reduce complications, and streamline care delivery.”
That kind of conviction, from someone who has spent a career in the operating room and the boardroom, is exactly what Linear needs to scale.
What This Means for Linear
Commercializing a medical device is fundamentally a trust-building exercise. Clinicians and hospital systems don’t adopt new technology quickly — they need validation from people they respect. As Linear’s COO and CCO Renae Franz put it: “His network and credibility open doors that would otherwise take years to open.”
Dr. Robbins doesn’t just bring a name to the letterhead. He brings a deep understanding of how innovations move from concept to clinical practice, built through decades of doing exactly that at some of the most respected institutions in American medicine.
The Plains Ventures Perspective
We back exceptional teams solving real problems, and we work hard to surround those teams with the expertise and network they need to succeed. Dr. Robbins’ addition to Linear is a direct expression of that commitment.
As Justin Wilson, President and Managing Director of Plains Ventures, noted: “Dr. Robbins’ career — from the operating room to the boardroom — represents exactly the kind of credibility and connectivity that can accelerate a company like Linear from promising innovation to market leader.”
This is what early-stage investing looks like when it’s working. A founder with a clear mission, a product that solves a real problem, the right capital behind it, and now the right clinical champion to bring it to the patients and clinicians who need it most.
We’re proud to be Linear’s lead investor. And we’re just getting started.
To learn more about Linear Health Sciences and the Orchid Safety Release Valve, visit linearsciences.com.